REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Share News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,906.00
Bid: 1,902.00
Ask: 1,910.00
Change: 14.00 (0.74%)
Spread: 8.00 (0.421%)
Open: 1,852.00
High: 1,908.00
Low: 1,852.00
Prev. Close: 1,892.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus shares plunge as expects adjusted profit and revenue decline

Thu, 15th Feb 2024 09:41

(Alliance News) - Genus PLC on Thursday warned that Chinese porcine markets continued to be "challenging", as it anticipates reporting lower revenue and adjusted pretax profit for its recent half-year.

Shares in the Basingstoke, England based animal genetics biotechnology company focused on cattle and pig farms plunged 30% to 1,478.00 pence each on Thursday morning in London.

Genus expects to report adjusted pretax profit for the financial first-half ended December 31 of GBP29 million on revenue of GBP334 million.

Both outcomes will be in line with expectations, but they would represent a 31% slump in adjusted pretax profit from GBP42.2 million a year before and a 4.6% decline on the top line from GBP350.2 million.

"[Pig Improvement Co] ex-China performed robustly, with North America, Latin America and Europe delivering adjusted operating profit growth in constant currency. China continues to be a challenging porcine market, however our enhanced commercial focus has resulted in winning new royalty customers in the period which will positively impact fiscal year 2025 and beyond," Genus added.

PIC sales comprise semen, embryos and breeding animals with 'superior' genetics to those animals currently on farms.

Genus said: "With regards to our PRP programme, recent engagement with the US Food & Drug Administration has shifted to the post-approval compliance procedures. This has clarified the data submissions and monitoring that will be required on an ongoing basis post-PRP approval. Validation of our procedures to comply with these monitoring requirements is expected to take several months. We therefore now expect FDA approval in fiscal year 2025. Our dialogue shifting to the post-approval compliance procedures reinforces our view that approval will be forthcoming. There are no changes to our commercialisation timeline or financial projections."

Genus's PRP programme focuses on pigs who are resistant to porcine reproductive and respiratory syndrome, or PRRS. Genus has developed a solution to protect pigs from the PRRS virus, which causes animal suffering and prematurely kills millions of pigs every year.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
18 Nov 2020 15:59

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
12 Nov 2020 15:57

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
10 Sep 2020 09:28

UK BROKER RATINGS SUMMARY: Hargreaves Lansdown, Rio Tinto Get Upgrades

UK BROKER RATINGS SUMMARY: Hargreaves Lansdown, Rio Tinto Get Upgrades

Read more
8 Sep 2020 09:40

Genus Profit Surges In Full Year As Revenue And Value Of Assets Rises

Genus Profit Surges In Full Year As Revenue And Value Of Assets Rises

Read more
8 Sep 2020 08:40

Restockng drive in China sees Genus's free cash flow more than triple

(Sharecast News) - Genus posted a big uplift in profits before tax with cash flows more than tripling thanks to strong sales in China.

Read more
1 Sep 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
29 Jun 2020 09:20

Genus Appoints Former Tate & Lyle Boss Ferguson As Chair Designate

Genus Appoints Former Tate & Lyle Boss Ferguson As Chair Designate

Read more
29 Jun 2020 07:55

LONDON MARKET PRE-OPEN: Genus Gets New Chair; Indivior Promotes CFO

LONDON MARKET PRE-OPEN: Genus Gets New Chair; Indivior Promotes CFO

Read more
18 Jun 2020 09:40

UK BROKER RATINGS SUMMARY: Berenberg Downgrades Carnival To Sell

UK BROKER RATINGS SUMMARY: Berenberg Downgrades Carnival To Sell

Read more
12 Jun 2020 10:23

Baillie Gifford UK Growth Net Asset Value Falls But Beats Benchmark

Baillie Gifford UK Growth Net Asset Value Falls But Beats Benchmark

Read more
30 Apr 2020 09:45

UK BROKER RATINGS SUMMARY: ODDO BHF Cuts IAG To Neutral From Buy

UK BROKER RATINGS SUMMARY: ODDO BHF Cuts IAG To Neutral From Buy

Read more
30 Apr 2020 08:09

LONDON BRIEFING: Shell Cuts Dividend As Earnings Drop Almost 50%

LONDON BRIEFING: Shell Cuts Dividend As Earnings Drop Almost 50%

Read more
20 Apr 2020 15:56

Director dealings: Genus' company secretary lowers stake

(Sharecast News) - Genus revealed on Monday that general counsel and company secretary Dan Hartley had offloaded 7,500 ordinary shares in the FTSE 250-listed animal semen merchant.

Read more
20 Apr 2020 14:07

UK DIRECTOR DEALINGS SUMMARY: Genus Senior Exec Sells GBP270,000 Worth

UK DIRECTOR DEALINGS SUMMARY: Genus Senior Exec Sells GBP270,000 Worth

Read more
15 Apr 2020 15:35

FTSE 250 movers: JD Wetherspoon hit by expectations for prolonged period of low demand

(Sharecast News) - Leisure-related shares paced declines on the second-tier index on Wednesday, as investors' attention pivoted back to the sector as risk appetite soured on the back of exceedingly weak economic reports and corporate updates Stateside.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.